A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics
This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728 tablets in subjects with advanced solid tumor or hematologic tumor.
Advanced Solid Tumor or Hematologic Tumor
DRUG: TQB3728
Maximum tolerated dose (MTD), MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT., Baseline up to 28 days
Tmax, To characterize the pharmacokinetics of TQB3728 by assessment of time to reach maximum plasma concentration., 30minutes pre-dose on day 1and day 8;1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.|Cmax, Cmax is the maximum plasma concentration of TQB3738 or metabolite(s)., 30minutes pre-dose on day 1and day 8;1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.|AUC0-t, To characterize the pharmacokinetics of TQB3728 by assessment of area under the plasma concentration time curve from zero to specific time or infinity., 30minutes pre-dose on day 1and day 8; 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 24hour, 72hour post-dose on day 1 and day 8; 48hour, 96hour post-dose on day 1.|Progression-free survival (PFS), PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause., up to 48 weeks|Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 48 weeks
This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728 tablets in subjects with advanced solid tumor or hematologic tumor.